RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
MicuRx Pharma, a San Francisco-Shanghai company, closed a $15 million financing, which it will use to complete a China Phase III trial of its oral antibiotic, contezolid (MRX-I). MicuRx expects the trial will finish in 2018. Contezolid treats serious infections caused by Gram positive bacteria, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE) without causing myelosuppression. The funding was led by China affiliates of Delian Capital and BVCF, both of whom are existing MicuRx investors.
Source: China Biotoday